ΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ. Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος

Similar documents
Genetic Cardiomyopathies

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες

Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD

Cardiomyopathy in Fabry s disease

HCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT

Inherited Arrhythmia Syndromes

Cardiac Considerations and Care in Children with Neuromuscular Disorders

Clinical Genetics in Cardiomyopathies

ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ

ECG Underwriting Puzzler Dr. Regina Rosace AVP & Medical Director

Inherited Cardiomyopathies Molecular genetics and Clinical genetic testing

HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?

Arrhythmogenic Cardiomyopathy cases. Δέσποινα Παρχαρίδου Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογική κλινική ΑΧΕΠΑ

LVH GREY ZONE OF HYPERTROPHIED VENTRICLES

Το ΗΚΓ στις Μυοκαρδιοπάθειες και στην Περικαρδίτιδα

Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA. Disclosures: Medtronic (Grantee) GeneDx (Consultant)

Update in Cardiomyopathies: Their New Classifications and Importance of Mixed Phenotypes

Cardiac follow-up in patients with hereditary muscular diseases

at least 4 8 hours per week

6/19/2018. Background Athlete s heart. Ultimate question. Applying the International Criteria for ECG

EVALUATION OF ELECTROCARDIOGRAPHIC FINDINGS IN ATHLETES

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !

Sudden cardiac death: Primary and secondary prevention

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness

Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;

Athletes with cardiac disease; dead and buried or chance for resurrection?

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Paediatric ECG Interpretation

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

Atrial Cardiomyopathy is it relevant?

Risk prediction in inherited conditions Laminopathies

Tachycardia Devices Indications and Basic Trouble Shooting

Acquired conduction disturbance in structurally normal heart in children. Mi Young Han, M.D.,PhD. Kyung Hee University Hospital

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Normal ECG And ECHO Findings in Athletes

Ασυμπτωματικός ασθενής με διαταραχές αγωγής. Πρόγνωση θεραπεία

Antony French Consultant Cardiologist & Electrophysiologist

EHRA/EUROPACE 2011 Madrid, Spain June

Dr. Schroeder has no financial relationships to disclose

DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY. David SIU MD ( 蕭頌華醫生 ) Division of Cardiology The University of Hong Kong

Rebuttal. Jerónimo Farré MD 2010

Tehran Arrhythmia Center

Paroxysmal Supraventricular Tachycardia PSVT.

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada

Declaration of conflict of interest. I have nothing to disclose.

La valutazione dell atleta: è una strategia salva-vita e costo-efficace?

Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:

PAEDIATRIC ECG Dimosthenis Avramidis, MD.

What s new in Hypertrophic Cardiomyopathy?

Office ECG Interpretation

EKG screening in athletics

Hypertrophic Cardiomyopathy

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015

ΔΙΑΤΑΡΑΧΕΣ ΕΝΔΟΚΟΙΛΙΑΚΗΣ ΑΓΩΓΙΜΟΤΗΤΑΣ ΔΗΜΗΤΡΙΟΣ Δ. ΜΑΝΩΛΑΤΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΕΡΓΑΣΤΗΡΙΟ ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ Γ.Ν.Α.

DEPARTMENT NAME PRE-PARTICIPATION SCREENING THE SPORTS PHYSICAL

Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases

Interpretation and Consequences of Repolarisation Changes in Athletes

Definition and classification of the cardiomyopathies. Georgios K Efthimiadis Ass Prof of Cardiology

Reading Assignment (p1-91 in Outline ) Objectives What s in an ECG?

Profiles in Prognosis for HCM

LES NOUVEAUX TROUBLES DE CONDUCTION HEREDITAIRES

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.

EPS Case presentation Looks like VT but it isn t!

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

ECG S: A CASE-BASED APPROACH December 6,

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology

Prevention of Sudden Death in ARVC

European Society of Cardiology Working Group on Myocardial & Pericardial Diseases

Left ventricular non-compaction: the New Cardiomyopathy on the Block

Contribution of genetics for sudden death risk stratification in dilated cardiomyopathy

Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations

Blocks & Dissociations. Reading Assignment (p47-52 in Outline )

HYPERTROPHY: Behind the curtain. V. Yotova St. Radboud Medical University Center, Nijmegen

Importance of CRT team for optimization of the results: a European point of view

Heart Rhythm Disorders. How do you quantify risk?

What Clinicians Need to Know About Genetic Testing for Patients and Families with HCM

Endurance Exercise and Cardiovascular Health

ECG Interpretation. Best to have a system to methodically evaluate ECG (from Dubin) * Rate * Rhythm * Axis * Intervals * Hypertrophy * Infarction

Skeletal myopathy in a family with lamin A/C cardiac disease

Diploma in Electrocardiography

ΔΠΔΜΒΑΣΙΚΗ ΘΔΡΑΠΔΙΑ ΚΟΙΛΙΑΚΩΝ ΑΡΡΤΘΜΙΩΝ

CRF procedure PROCEDURE FLOW. PATIENT ASSESSMENT Symptoms and indication. Pacemaker & ICD registration. Procedures. Procedure ICD.

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Pre-Participation Athletic Cardiac Screening

Silvia G Priori MD PhD

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

Bundle Branch & Fascicular Blocks. Reading Assignment (p53-58 in Outline )

ECG Cases and Questions. Ashish Sadhu, MD, FHRS, FACC Electrophysiology/Cardiology

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

Improving Patient Outcomes with a Syncope Center. Suneet Mittal, MD

CARDIOMYOPATHY IN CT. Hans- Christoph Becker Professor of Radiology

Etiology, Classification & Management. Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Utility of Echocardiography

Heart Failure. GP Update Refresher 18 th January 2018

Role of CMR in heart failure and cardiomyopathy

Patient Susceptibilities in Preclinical Drug Safety Assessment

YES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS

Lee Chee Wan. Senior Consultant Pacing and Cardiac Electrophysiology. GP Symposium 2 nd April 2016

Clinical Indications for Echocardiography

Transcription:

ΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος Β Καρδιολογική Κλινική, ΠΓΝΑ «Ο ΕΥΑΓΓΕΛΙΣΜΟΣ»

CONFLICT of INTEREST : none declared

CLASSIFICATION OF THE CARDIOMYOPATHIES: a position statement from the ESC Working Group on myocardial and pericardial diseases Eur Heart Journal 2008...we define a cardiomyopathy as: A myocardial disorder in which the heart muscle is structurally and functionally abnormal, in the absence of CAD, hypertension, valvular disease and CHD sufficient to cause the observed myocardial abnormality phenotype RED FLAGS genotype unexplained bradycardia ± AVD = RED FLAG

Cardiomyopathies and Cardiac Conduction Disturbances HCM FABRY (GLA) DANON (LAMP2) AMPK (PRKAG2) DCM RCM Other phenotypes LMNA EMD SCN5A DES SCN5A

HCM phenotype

FABRY DISEASE familial storage disease (metabolic cardiomyopathy) caused by a deficiency of the lysosomal enzyme A-galactosidase A (a- Gal) substrate accumulation Stroke, ear, eye, CNS heart angiokeratoma renal ANS vacuolization in lysosomes acroparesthesia

Θολερότης φακού και κερατοειδούς, µε φυσιολογική όραση «Fabry cataract» Split-lamp Life expectancy: 40yrs Prevalence : 6-8% of concentric LVH Delay in diagnosis : 14 years!!

Pacemaker in 10-20% Prevalence : 8% of concentric LVH - Sinus bradycardia - Short PR - Later AVB DIAGNOSIS - αgal activity - biopsy - Genetic analysis MRI Concentric LVH LGE basal-mid posterolateral

crusial! Distinguish FABRY from HCM is

X-linked dominant lysosomal disease, due to a primary deficiency of lysosome-associated membrane protein 2 caused by several mutations in the LAMP2 gene DANON DISEASE Pathological hallmark: intracytoplasmic vacuoles containing autophagic material and glycogen in cardiac and skeletal muscle cells. Prevalence : 6-8% of concentric LVH

Phenotype: cardiomyopathy (88%, HCM), skeletal myopathy (muscle weakness, CPK), liver, retina, lungs, mental retardation (70%). Early onset (mean age 17yrs), women later (mild disease, HCM + DCM). ECG: - very high voltage of LV - inverted T waves - WPW (35%) Echo: - massive LVH, mostly concentric

There is no specific treatment for Danon disease, except heart transplantation! ICD fails to terminate lethal ventricular tachyarrhythmias in most Cheng at al. EHJ 2012 Marron editorial. EHJ 2012 crusial! Distinguish HCM from DANON is Danon is characterized by early morbidity and limited life expectancy, with survival beyond 25yrs uncommon! 65mm The DANON REGISTRY reports the following disease landmarks on average: First symptoms 12yrs, rapid deterioration (6mo), transplant 18yrs, death without transplant 19yrs boy, 12 27yrs old

(AMP kinase) 19yo, PR PRKG2 mutation The AMP kinase is enzyme system that appears to act as a fuel gauge in cells, as a modulator of ATP sensitivity to cellular energy requirements. PRKG2 mutations may cause LVH mimicking HCM + (WPW and AVB) + skeletal myopathy ECG: gradual changes, unrelated to LVH progression. 28yo, rsr + LAH LVH slowly progressive Myopathy : 15%, severe myalgia during/ after short burst of aerobic exercise. Proximal skeletal myopathy. EMG may be normal. Biopsy: mitochondrial proliferation with minimal excess glycogen

DCM phenotype

LAMINOPATHIES The LMNA gene encodes nuclear lamin A and C, intermediate filament proteins that are components of the nuclear lamina. LMNA = 5-8% of DCM pts Lu. LMNA. Disease Models and Mechanisms 2011

CARDIAC INVOLVEMENT : DCM ± ARRHYTHMIC DISORDERS Progression of age-related phenotypes in LMNA Patients with LMNA may present a wide range of arrhythmic disturbances, either bradyarrhytmias (conduction disturbances and AV-blocks, sinus node dysfunction, atrial standstill) or tachyarrhythmias (AF, VT, VF), in variable combinations, and with frequent association with LV dysfunction and HF. Severity of arrhythmias is usually not related to the presence and degree of neuromuscular impairment. Emery Dreifuss muscular dystrophy: wasting of humeral muscle + elbow contracture AVB, later DCM

Index case AF with complete AVB, LBBB Male, 64yrs old, aborted SD LBBB, AF from 40y EF~48% MRI : IVS mid-wall LGE (fibrosis) LMNA mutation ICD. 6 months later: VT from basal IVS - ablation Wenckebach Son, asymptomatic ECG EF normal No MRI LMNA mutation ICD for primary prevention

JACC 2012

LAMINOPATHIES are a functional continuum of related disorders rather than separate diseases. In this setting, each phenotype may be mistakenly considered as a specific diagnosis by physicians working without a pedigree or long-term follow-up. Cardiology 2011 H. Boudoulas et al.

Ion channel SCN5A mutation DCM Male 47yo. LBBB when 30yo. DCM+AF Most genes associated with DCM encode for structural proteins involved with contractile function and the cytoskeletal matrix. Discovery of mutation in gene SCN5A associated with DCM suggests that dysfunction in electrical excitability, caused by disruption of sodium channel function, Male 41yo. AF/RBBB when 22. Normal EF also leads to dilation remodeling. Common phenotype: Early AVB, SN dysfunction, AF, years later DCM

Desminopathies are heterogeneous group of severe, dominantly inherited myopathies, often accompanied by cardiomyopathy, with syncope or sudden death due to conduction defects. (DCM, IVNC, RCM). Onset and progression are variable. DESMIN myopathy/cardiomyopathy

Health [in] Code

Cardiologists don t think in cardiac conduction disturbances like an important entity 4 requests in the last 2 years! Health [in] Code

Cardiology 2011 H. Boudoulas et al.

ΕΥΧΑΡΙΣΤΩ για την προσοχή σα